BMD Correlates with Number of HIV Regimens (CME/CE)
The number of HIV treatment regimens a patient undergoes appears to correlate with loss of bone mineral density (BMD), researchers reported here at the International Aids Society Conference on HIV Pathogenesis, Treatment, and Prevention.
Saturday, August 10, 2013
Tuesday, August 6, 2013
Blood Test May Flag Impending COPD Flares (CME/CE)
Blood Test May Flag Impending COPD Flares (CME/CE)
Easily measured biomarkers of inflammation could give advance warning of chronic obstructive pulmonary disease (COPD) exacerbations, researchers said.
When COPD patients in a prospective Danish study had high levels of C-reactive protein (CRP), serum fibrinogen, and leukocyte count, their risk of experiencing a disease flare during the following year was increased by a factor of 2.5 (95% CI 1.8-3.4) compared with patients who did not have high values for any of these measures, according to Børge Nordestgaard, DMSc, of Copenhagen University Hospital in Denmark, and colleagues.
Easily measured biomarkers of inflammation could give advance warning of chronic obstructive pulmonary disease (COPD) exacerbations, researchers said.
When COPD patients in a prospective Danish study had high levels of C-reactive protein (CRP), serum fibrinogen, and leukocyte count, their risk of experiencing a disease flare during the following year was increased by a factor of 2.5 (95% CI 1.8-3.4) compared with patients who did not have high values for any of these measures, according to Børge Nordestgaard, DMSc, of Copenhagen University Hospital in Denmark, and colleagues.
Monday, August 5, 2013
Switch to Quad Pill Maintained HIV Suppression (CME/CE)
Switch to Quad Pill Maintained HIV Suppression (CME/CE)
HIV patients can be successfully switched from a twice-daily integrase inhibitor regimen to a once-daily, single-tablet regimen without loss of viral suppression, researchers reported here.
At 48 weeks, all 46 patients who switched from a raltegravir-based (Isentress) regimen to the four-drug, elvitegravir-cobicistat-tenofovir-emtricitabine (Stribild) pill were able to maintain undetectable viral load using the 50 copies/ml assay, said Gordon Crofoot, MD, a Houston-based HIV researcher in private practice.
HIV patients can be successfully switched from a twice-daily integrase inhibitor regimen to a once-daily, single-tablet regimen without loss of viral suppression, researchers reported here.
At 48 weeks, all 46 patients who switched from a raltegravir-based (Isentress) regimen to the four-drug, elvitegravir-cobicistat-tenofovir-emtricitabine (Stribild) pill were able to maintain undetectable viral load using the 50 copies/ml assay, said Gordon Crofoot, MD, a Houston-based HIV researcher in private practice.
Sunday, August 4, 2013
Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)
Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)
HIV patients with mild to moderate renal impairment appear to tolerate treatment with a combination tablet that contains drugs known to impact kidney function, a phase III, open-label, two-cohort study found.
The treatment group receiving the four-drug combination of elvitegravir, cobicistat, tenofovir DF, and emtricitabine, branded as Stribild, saw a small impact on estimated creatinine clearance (eCCr), but the change rapidly plateaued and may not be clinically meaningful, Frank Post, MD, a reader in HIV at Kings College Hospital in London, told MedPage Today
HIV patients with mild to moderate renal impairment appear to tolerate treatment with a combination tablet that contains drugs known to impact kidney function, a phase III, open-label, two-cohort study found.
The treatment group receiving the four-drug combination of elvitegravir, cobicistat, tenofovir DF, and emtricitabine, branded as Stribild, saw a small impact on estimated creatinine clearance (eCCr), but the change rapidly plateaued and may not be clinically meaningful, Frank Post, MD, a reader in HIV at Kings College Hospital in London, told MedPage Today
Subscribe to:
Posts (Atom)